enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary
enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.
How this was made
The 30-second read
Why it matters
The report provides fresh quantitative data and a regulatory timeline, informing short‑ to medium‑term trading decisions.
Market read
New earnings and trial data create a mixed signal for the stock, with downside from loss but upside from upcoming BLA.
What to watch
Potential partnership or licensing deals not disclosed could mitigate cash concerns.
Background
enGene Therapeutics filed its 10‑Q for Q3 FY2026, revealing financials and clinical progress.
Ticker impact
10-Q reports Q3 FY2026 net loss of $32.5M, EPS -$0.47 and Phase 2 LEGEND data with 54% CR, plus BLA filing plan Q4 2026.
Potential short-term pressure from loss, medium-term upside on FDA engagement.
Earnings miss and cash runway concerns weigh negative, but strong trial readout and regulatory timeline add upside catalyst.
Market effects
Biotech sector may see modest lift as trial data supports gene‑therapy pipeline confidence.
US biotech investors could adjust exposure to early‑stage gene therapy firms.
Limited; primarily affects US‑listed biotech niche.
Counterpoint
Losses and cash burn suggest valuation compression; trial data may not translate to commercial success.
Key entities
- companyenGene Therapeutics Inc.
Biotech firm developing gene‑therapy for bladder cancer.
